Twist Bioscience continues to demonstrate robust top-line momentum, with revenue growing 23.2% year-over-year to $118.4M in 2026Q3, marking the fourteenth consecutive quarter of growth. However, the company remains deeply unprofitable, with an operating margin...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 23.2% year-over-year in 2026Q3, but gross margin plateaued at 52.8% and operating margin remained deeply negative at -30.6%, with SG&A consuming 68% of revenue.
Twist Bioscience's silicon-based DNA synthesis enables high-precision, high-throughput manufacturing, giving it a competitive edge in synthetic biology.
The company's platform supports research across medicine, agriculture, industrial biology, and biopharma, broadening its revenue potential.
Multiple bullish theses highlight Twist Bioscience's growth potential, with analysts summarizing positive outlooks on its stock performance.
Trailing total returns as of 9/23/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | -$0.56-10.6% vs -$0.51 | $118M+3.4% vs $115M |
Q2 2026 May 4, 2026 | -$0.71-44.9% vs -$0.49 | $111M+2.9% vs $108M |
Q1 2026 Feb 2, 2026 | -$0.50-4.2% vs -$0.48 | $104M+1.8% vs $102M |
Q4 2025 Nov 14, 2025 | -$0.45+10.0% vs -$0.50 | $99M+1.7% vs $97M |
Twist Bioscience Corporation (NASDAQ:TWST) on Wednesday announced an agreement with Lilly TuneLab, a collaborative AI/ML drug discovery platform created by Eli Lilly and Co. (NYSE:LLY).
[url="]Twist Bioscience Corporation[/url] (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced an agreement with Lilly TuneLab, a collabo
If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In.
Benchmark TWST against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Twist Bioscience Corporation (TWST)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $164.60 | $10.25B | -126.62 | 20.32% | -20.63% | -16.43% | — | |
| $247.46 | $37.44B | 45.41 | -0.78% | 18.36% | 31.08% | — | |
| $1.47 | $456.58M | -0.81 | 3.89% | -82.49% | -4961.74% | — | |
| $25.93 | $2.67B | -32.01 | 120.01% | -54.75% | -7.7% | — | |
| $12.69 | $1.42B | -3.33 | 16.92% | -672.16% | -57.79% | — | |
| $177.16 | $23.49B | -53.36 | 32.88% | -38.33% | — | — |
Twist Bioscience Corporation (TWST) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Twist Bioscience Corporation (TWST) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 5, 2026·SEC
Aug 3, 2026·SEC
May 4, 2026·SEC
Nov 17, 2025·SEC
Get notified when TWST posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Twist Bioscience Corporation (TWST) stock FAQ — growth, dividends, profitability & financials explained
Twist Bioscience Corporation (TWST) reported $431.8M in revenue for fiscal year 2025. This represents a 18930% increase from $2.3M in 2016.
Twist Bioscience Corporation (TWST) grew revenue by 20.3% over the past year. This is strong growth.
Twist Bioscience Corporation (TWST) reported a net loss of $136.7M for fiscal year 2025.
Twist Bioscience Corporation (TWST) has a return on equity (ROE) of -16.4%. Negative ROE indicates the company is unprofitable.
Twist Bioscience Corporation (TWST) had negative free cash flow of $93.1M in fiscal year 2025, likely due to heavy capital investments.
